Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial.
来源：PubMed发布日期：2026-07-01作者：Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT0 次点击